DUROLANE

References

  1. Hunter DJ, Felson Osteoarthritis. BMJ. 2006;332(7542):639-42.
  2. Nelson AE, Osteoarthritis year in review 2017: clinical, Osteoarthritis and Cartilage (2017), https://doi.org/10.1016/j.joca.2017.11.014.
  3. American Academy of Orthopaedic Arthritis of the knee. Last updated June 2014.
  4. Arthritis Hyaluronic acid injections for osteoarthritis. Accessed May 8, 2016.
  5. National Institute of Arthritis and Musculoskeletal and Skin Osteoarthritis. Last updated May 30, 2016.
  6. Hochberg MC, Altman RD, April KT, et American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-74.
  7. Edsman K, Hjelm R, Lärkner H, et Intra-articular duration of Durolane™ after single injection into the rabbit knee. Cartilage. 2011;2(4)384-8.
  8. Balazs EA, Denlinger Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:3-9.
  9. International Cartilage Repair What is cartilage?. Accessed July 16, 2015.
  10. Blagojevic M, Jinks C, Jeffery A, Jordan Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2010;18(1):24-33.
  11. Ding C, Cicuttini F, Blizzard L, Jones Genetic mechanisms of knee osteoarthritis: a population- based longitudinal study. Arthritis Res Ther. 2006;8(1):R8. doi: 10.1186/ar1835.
  12. Leighton R, Åkermark C, Therrien R, et NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014;22(1):17-25.
  13. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta- analysis. Ann Intern Med. 2015;162(1):46-54.
  14. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee J Arthritis. 2013;2(1):108. doi: 10.4172/2167-7921.1000108.
  15. Krocker D, Matziolis G, Tuischer J, et Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid. Z Rheumatol. 2006;65(4):327-31.
  16. Ågerup B, Berg P, Åkermark Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. BioDrugs. 2005;19(1):23-30.
  17. Altman R, Lim S, Steen G, Dasa Intra-articular hyaluronic acid delays total knee replacement (TKR) in patients with knee OA: evidence from a large U.S. health claims database. PLoS One. 2015;10(12):e0145776.
  18. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017
  19. Altman RD, Åkermark C, Beaulieu AD, Schnitzer T. Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patient with osteoarthritis of the knee. Osteoarthritis Cartilage. 2004;12(8):642-9
  20. Zhang H, Zhang K, Zhang X, et al. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. Arthritis Res Ther. 2015;17:51. doi: 10.1186/s13075-015-0557-x.
  21. Lindqvist U, Tolmachev V, Kairemo K, Åström G, Jonsson E, Lundqvist H. Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41(8):603-13.
  22. Larsen NE, Dursema HD, Pollak CT, Skrabut EM. Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. J Biomed Mater Res B Appl Biomater. 2012;100(2):457-6.
  23. Sakamoto T, Mizuno S, Miyazaki K, et al. Biological fate of sodium hyaluronate (SPH) (1) studies on distribution, metabolism and excretion of 14C-SPH in rabbits after intraarticular administration. Pharmacometris. 1984;28(2):375-87.

Bioventus

Summary of Indications for Use
DUROLANE (3 mL): ): Symptomatic treatment of mild to moderate knee osteoarthritis. There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.

Risks can include transient pain, swelling and/or stiffness at the injection site. Full prescribing information can be found in product labeling, or at DUROLANE.com.

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

© 2018. Bioventus LLC.

Durolane-since-2001
*First introduced in the European Union in 2001.

To learn more about DUROLANE or for contact information, please select your location to continue.